시장보고서
상품코드
1513882

세계의 항감염제 시장

Anti-Infectives

발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 116 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항감염제 세계 시장, 2030년까지 2,313억 달러에 달할 전망

2023년 1,518억 달러로 추정되는 세계 항감염제 시장은 2023-2030년 동안 연평균 6.2% 성장하여 2030년에는 2,313억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 항바이러스제는 CAGR 7.3%를 기록하여 분석 기간 종료 시점에 1,171억 달러에 도달할 것으로 예상됩니다. 항진균제 부문은 분석 기간 동안 CAGR 4.9%로 성장할 것으로 예상됩니다.

미국 시장 394억 달러, 중국은 연평균 10.1% 성장할 것으로 전망

미국의 항감염제 시장은 2023년 394억 달러에 달할 것으로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 576억 달러의 시장 규모에 도달할 것으로 예상되며, 2023-2030년 분석 기간 동안 10.1%의 CAGR을 기록할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 3.3%와 4.7%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 약 4.2%의 CAGR로 성장할 것으로 예상됩니다.

항감염제 - 주요 동향 및 촉진요인

항감염제는 현대 의학의 핵심으로 박테리아, 바이러스, 곰팡이, 기생충에 의한 감염에 대처하기 위한 다양한 약물로 구성되어 있습니다. 이 광범위한 범주에는 항생제, 항바이러스제, 항진균제, 항기생충제 등이 포함되며, 각각은 다양한 감염성 질환의 치료에 중요한 역할을 합니다. 항감염 약물의 개발과 사용은 이환율과 사망률을 크게 감소시켜 한때 치명적이라고 여겨졌던 질병의 치료에 혁명을 일으켰습니다. 지난 수십 년 동안 생명공학 및 제약 연구의 혁신은 새로운 화합물의 발견과 기존 약물의 개선으로 이어져 약물의 효능을 향상시키고 부작용을 감소시켰습니다. 항생제 내성이라는 현재 진행 중인 과제는 여전히 이 분야에서 중요한 초점이 되고 있습니다. 항생제 남용과 오남용은 약제 내성 병원균의 출현을 가속화하여 공중 보건에 심각한 위협이 되고 있습니다. 따라서 내성 감염을 퇴치하기 위한 새로운 항생제 및 박테리오파지, 단클론항체, 면역요법과 같은 대체 요법을 발견하기 위해 연구 개발에 많은 투자가 이루어지고 있습니다.

세계 건강 동향과 전염병 역학은 항감염제 시장에 큰 영향을 미치고 있으며, COVID-19의 원인인 신종 코로나 바이러스와 같은 새로운 병원체의 출현은 강력한 항감염 전략의 필요성을 강조하고 있습니다. 대규모 백신 접종 프로그램, 공중보건 노력, 위생 환경 개선은 감염병을 통제하는 데 중요한 역할을 해왔습니다. 그러나 전염병의 위협은 끊임없이 존재하기 때문에 항감염 약품의 지속적인 발전이 필요합니다. 진단 기술의 급속한 발전으로 감염병을 신속하고 정확하게 발견할 수 있게 되었습니다. 이를 통해 적시에 적절한 치료를 할 수 있게 되어 감염성 질환의 부담을 줄일 수 있습니다. 또한, 세계화, 국제 여행 및 무역의 증가로 인해 감염병이 국경을 넘어 전파될 위험이 증가하고 있습니다. 고도의 감시 시스템과 국제 협력을 통해 감염병 발생을 감시하고 통제하기 위한 노력은 시장의 역동적인 특성과 끊임없는 혁신의 필요성을 더욱 강조하고 있습니다.

항감염제 시장의 성장은 여러 가지 요인에 의해 주도되고 있습니다. 고성능 스크리닝, 인공지능, 유전체 연구 등 신약 개발 및 약물 개발의 기술 발전은 잠재적인 항감염증 약물의 식별을 가속화하고 있습니다. 이러한 기술은 병원균을 보다 정확하게 표적화하여 약물의 효능을 향상시키고 내성균 발생 가능성을 감소시킬 수 있습니다. 암, 당뇨병, HIV 등 감염에 대한 감수성을 높이는 만성 질환과 면역 결핍의 유병률이 증가함에 따라 효과적인 항감염 치료에 대한 수요가 증가하고 있습니다. 소비자 행동도 중요한 역할을 하고 있으며, 건강 및 웰빙에 대한 인식이 높아지고 적극적인 접근이 시장 확대에 기여하고 있습니다. 신흥 시장의 의료 인프라 확대와 의료 서비스 접근성 향상으로 항감염제 소비가 더욱 증가하고 있습니다. 신속한 승인과 항균제 내성 연구에 대한 자금 지원과 같은 규제적 인센티브가 이 시장의 성장을 뒷받침하고 있습니다. 제약사, 학계, 정부 기관들의 협력은 이 부문의 혁신과 개발을 촉진하여 새롭고 효과적인 항감염증 약물의 지속적인 파이프라인을 보장하고 있습니다. 또한, 민관 파트너십과 세계 보건 이니셔티브는 미충족 수요에 대응하는 데 필수적이며, 전 세계 감염병 퇴치에 필수적인 의약품의 개발과 유통을 촉진하고 있습니다.

조사 대상 기업 예시(17개사)

  • Allergan PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 24.07.24

Global Anti-Infectives Market to Reach US$231.3 Billion by 2030

The global market for Anti-Infectives estimated at US$151.8 Billion in the year 2023, is expected to reach US$231.3 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2023-2030. Anti-Viral Drugs, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$117.1 Billion by the end of the analysis period. Growth in the Anti-Fungal Drugs segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$39.4 Billion While China is Forecast to Grow at 10.1% CAGR

The Anti-Infectives market in the U.S. is estimated at US$39.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$57.6 Billion by the year 2030 trailing a CAGR of 10.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Anti-Infectives - Key Trends and Drivers

Anti-infectives are a cornerstone of modern medicine, comprising a diverse range of drugs designed to combat infections caused by bacteria, viruses, fungi, and parasites. This broad category includes antibiotics, antivirals, antifungals, and antiparasitics, each playing a crucial role in treating various infectious diseases. The development and use of anti-infectives have significantly reduced morbidity and mortality rates, revolutionizing the treatment of diseases that were once considered deadly. Over the past few decades, innovations in biotechnology and pharmaceutical research have led to the discovery of novel compounds and the enhancement of existing drugs, improving their efficacy and reducing side effects. The ongoing challenge of antibiotic resistance remains a significant focus within this field. The overuse and misuse of antibiotics have accelerated the emergence of drug-resistant strains of pathogens, posing a serious threat to public health. Consequently, substantial investment in research and development is directed towards discovering new antibiotics and alternative therapies, including bacteriophages, monoclonal antibodies, and immunotherapies, to combat resistant infections.

Global health trends and the epidemiology of infectious diseases heavily influence the anti-infectives market. The emergence of new pathogens, such as the novel coronavirus responsible for COVID-19, has underscored the critical need for robust anti-infective strategies. Large-scale vaccination programs, public health initiatives, and improved sanitation have played significant roles in controlling infectious diseases. However, the persistent threat of infections necessitates ongoing advancements in anti-infective drugs. Rapid progress in diagnostic technologies has also been instrumental, enabling quicker and more accurate detection of infections. This supports timely and appropriate treatment, reducing the burden of infectious diseases. Moreover, globalization, increased international travel, and trade have heightened the risk of cross-border transmission of infectious diseases, making a well-equipped arsenal of anti-infective drugs indispensable. Efforts to monitor and control outbreaks through advanced surveillance systems and international cooperation further highlight the market's dynamic nature and the need for continual innovation.

The growth in the anti-infectives market is driven by several factors. Technological advancements in drug discovery and development, such as high-throughput screening, artificial intelligence, and genomic studies, have accelerated the identification of potential anti-infective agents. These technologies allow for more precise targeting of pathogens, improving drug efficacy and reducing the likelihood of resistance development. The rising prevalence of chronic diseases and immunocompromised conditions, such as cancer, diabetes, and HIV, which increase susceptibility to infections, has heightened the demand for effective anti-infective therapies. Consumer behavior also plays a significant role, with increasing awareness and a proactive approach towards health and wellness contributing to market expansion. The expansion of healthcare infrastructure in emerging markets and improved access to healthcare services has further boosted the consumption of anti-infectives. Regulatory incentives, such as fast-track approvals and funding for antimicrobial resistance research, support the growth of this market. Collaborations between pharmaceutical companies, academic institutions, and government bodies are fostering innovation and development in the field, ensuring a continuous pipeline of new and effective anti-infective agents. Additionally, public-private partnerships and global health initiatives are crucial in addressing the unmet needs in the anti-infectives market, promoting the development and distribution of essential medicines to combat infectious diseases worldwide.

Select Competitors (Total 17 Featured) -

  • Allergan PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Anti-Infectives - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Drug-Resistant Infections Spurs Innovation
    • Technological Advancements in Drug Discovery and Development Accelerate Market Growth
    • Emergence of New Pathogens Expands Addressable Market Opportunity
    • Advances in Diagnostic Technologies Drive Adoption of Targeted Therapies
    • Globalization and Increased International Travel Throw the Spotlight on Cross-Border Transmission Risks
    • Growing Prevalence of Chronic Diseases and Immunocompromised Conditions Propels Demand
    • Regulatory Incentives and Fast-Track Approvals Sustain Growth of Anti-Infective Market
    • Public Health Initiatives and Vaccination Programs Enhances Control Measures
    • Rising Investment in Biotechnology and Pharmaceutical Research Spurs Development of Novel Compounds
    • Advancements in Nanotechnology for Drug Delivery Accelerate Demand for New Solutions
    • Impact of COVID-19 Pandemic on Anti-Infective Strategies Propels Market Awareness
    • Environmental and Ecological Changes Drive Adoption of New Anti-Infective Solutions
    • Shift Towards Sustainable and Eco-Friendly Drug Production Methods Impacts the Market
    • Demand for Multi-Functional and Combination Therapies Sustains Market Interest
    • Expansion of Telemedicine and Digital Health Platforms Drives Adoption of Anti-Infectives
    • Challenges of Antibiotic Overuse and Misuse: Here's the Story of the Growing Resistance Issue
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anti-Infectives Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Anti-Infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anti-Viral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anti-Viral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anti-Viral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anti-Fungal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anti-Fungal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Anti-Fungal Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Bacterial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-Bacterial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Anti-Bacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • JAPAN
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • CHINA
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • EUROPE
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Anti-Infectives by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • FRANCE
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • GERMANY
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Anti-Infectives by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • INDIA
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Anti-Infectives by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Anti-Infectives by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • AFRICA
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제